The interferons are a group of more than 20 glycoproteins produced by numerous body cells in response to the presence of viruses, double-stranded RNA, polypeptides, or bacterial products. All of them share the ability to inhibit viral replication and cell proliferation, and to regulate and modulate immune cells. From an immunologic point of view, interferons increase the expression of class I o...

A 44-year-old woman with multiple sclerosis (MS) receiving interferon (IFN)-beta-1a treatment was admitted to a local hospital for severe icterus and liver injury. She was transferred to our university hospital because fulminant hepatitis (FH) was suspected. She was diagnosed with acute-type FH based on hepatic coma, severe liver injury and liver failure, and she received plasma exchange and co...

The interferons are a group of more than 20 glycoproteins produced by numerous body cells in response to the presence of viruses, double-stranded RNA, polypeptides, or bacterial products. All of them share the ability to inhibit viral replication and cell proliferation, and to regulate and modulate immune cells. From an immunologic point of view, interferons increase the expression of class I o...

A 57-year old woman with a history of multiple sclerosis, treated with interferon beta-1a in the last 5 months, was referred for hyperpyrexia (>40°C) that persisted for 15 days. At admission, there was elevation of transaminases, anemia (hemoglobin 8.9 g/dL), thrombocytopenia (platelet 135,000/mm3), and hypofibrinogenemia (fibrinogen 1.26 g/L). C-reactive protein was 10.7 mg/dL, lactate dehy...

teric Disease “Burden of Illness” Studies. The global burden of nontyphoidal Salmonella gastroenteritis. Clin Infect Dis. 2010;50(6):882-889. 7. Chaudhry IA, Shamsi FA, Al-Dhibi H, Khan AO. Pediatric endogenous bacterial endophthalmitis: case report and review of the literature. J AAPOS. 2006; 10(5):491-493. 8. Corman LI, Poirier RH, Littlefield CA, Sumaya CV. Endophthalmitis due to Salmonella ...

Interferon (IFN) beta-1b was the first disease-modifying therapy to be approved for the treatment of multiple sclerosis (MS), and over 21 years of follow-up data demonstrate its efficacy and long-term safety profile. Following recent regulatory approvals in the USA and European Union, IFN beta-1b is now one of the seven disease-modifying therapies [intramuscular IFN beta-1a; subcutaneous (SC) I...

1. Gaines AR, Varricchio F. Interferon beta-1b injection site reactions and necroses. Mult Scler. 1998;4:70. 2. Aguilar G, Serrano C, Carmona M, Linares J, Serrano S. Necrosis cutánea por interferón alfa en paciente con melanoma. Actas Dermosifiliogr. 2006;97:539--42. 3. Beiske AG, Myhr KM. Lipoatrophy: a non-reversible complication of subcutaneous interferon-beta 1a treatment of multiple scler...

Objective: To evaluate the clinical efficacy of onceweekly intramuscular interferon beta-1a (IFN B1a, Avonex Biogen) in Iranian multiple sclerosis (MS) patients. Methods: A 12 months, single blind clinical trial conducted from January 2001 to September 2003. Eighty patients with definite MS age 20 to 50 years were allocated to two groups. The first group received 30 microgram (6MIU) IFN B1a wee...